$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox

$elox Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-Q Financial Statement

#000114420414009665 Filed on February 14, 2014

Income Statement

Concept	2014 Q1	2013 Q4	2012 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.170M	$860.0K	$640.0K
YoY Change	143.75%	34.38%	-23.81%
% of Gross Profit
Research & Development	$966.3K	$730.8K	$591.1K
YoY Change	96.07%	23.64%	-21.19%
% of Gross Profit
Depreciation & Amortization	$90.00K	$80.00K	$70.00K
YoY Change	28.57%	14.29%	16.67%
% of Gross Profit
Operating Expenses	$966.3K	$730.8K	$591.1K
YoY Change	96.07%	23.64%	-64.39%
Operating Profit	-$2.129M	-$1.589M	-$1.300M
YoY Change	103.87%	22.22%
Interest Expense	-$17.81K	-$30.73K	-$34.28K
YoY Change	-10.26%	-10.35%	-51.03%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$0.00
YoY Change
Pretax Income	-$2.150M	-$1.620M	-$1.270M
YoY Change	155.95%	27.56%	-16.99%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.147M	-$1.620M	-$1.270M
YoY Change	156.61%	27.54%	-17.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$7.414M	-$9.529M	-$21.17M
COMMON SHARES
Basic Shares Outstanding	5.042M shares		117.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q4	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.200M	$6.120M	$640.0K
YoY Change	292.41%	856.25%	-58.71%
Cash & Equivalents	$6.198M	$6.122M	$640.1K
Short-Term Investments
Other Short-Term Assets	$1.200M	$1.490M	$1.300M
YoY Change	-29.82%	14.62%	-21.69%
Inventory
Prepaid Expenses	$1.200M	$1.488M
Receivables
Other Receivables
Total Short-Term Assets	$7.398M	$7.610M	$1.940M
YoY Change	124.86%	292.29%	-39.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.992K	$3.512K	$10.00K
YoY Change	-70.08%	-64.88%	0.0%
Goodwill
YoY Change
Intangibles	$3.554M	$3.482M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$3.562M	$3.491M	$3.520M
YoY Change	-1.06%	-0.82%	-3.56%
TOTAL ASSETS
Total Short-Term Assets	$7.398M	$7.610M	$1.940M
Total Long-Term Assets	$3.562M	$3.491M	$3.520M
Total Assets	$10.96M	$11.10M	$5.460M
YoY Change	59.07%	103.32%	-20.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$324.9K	$477.6K	$1.090M
YoY Change	-52.91%	-56.18%	147.73%
Accrued Expenses	$730.4K	$616.9K	$470.0K
YoY Change	114.82%	31.26%	-41.25%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$2.190M	$2.200M
YoY Change	-100.0%	-0.45%	0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.055M	$3.282M	$3.750M
YoY Change	-67.23%	-12.49%	8.7%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$99.73K	$99.73K	$130.0K
YoY Change	-72.3%	-23.29%	-77.59%
Total Long-Term Liabilities	$99.73K	$99.73K	$130.0K
YoY Change	-72.3%	-23.29%	-77.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.055M	$3.282M	$3.750M
Total Long-Term Liabilities	$99.73K	$99.73K	$130.0K
Total Liabilities	$1.155M	$3.381M	$3.880M
YoY Change	-67.74%	-12.85%	-3.48%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$68.98K	$49.57K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.800M	$7.720M	$1.580M
YoY Change
Total Liabilities & Shareholders Equity	$10.96M	$11.10M	$5.460M
YoY Change	59.07%	103.32%	-20.41%

Cashflow Statement

Concept	2014 Q1	2013 Q4	2012 Q4
OPERATING ACTIVITIES
Net Income	-$2.147M	-$1.620M	-$1.270M
YoY Change	156.61%	27.54%	-17.0%
Depreciation, Depletion And Amortization	$90.00K	$80.00K	$70.00K
YoY Change	28.57%	14.29%	16.67%
Cash From Operating Activities	-$1.560M	-$1.420M	-$560.0K
YoY Change	-11.36%	153.57%	-53.72%
INVESTING ACTIVITIES
Capital Expenditures	-$160.0K	-$110.0K	-$100.0K
YoY Change	14.29%	10.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$160.0K	-$110.0K	-$100.0K
YoY Change	14.29%	10.0%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$1.505M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.790M	6.870M	0.000
YoY Change	-36.97%		-100.0%
NET CHANGE
Cash From Operating Activities	-1.560M	-1.420M	-560.0K
Cash From Investing Activities	-160.0K	-110.0K	-100.0K
Cash From Financing Activities	1.790M	6.870M	0.000
Net Change In Cash	70.00K	5.340M	-660.0K
YoY Change	-92.55%	-909.09%	-48.84%
FREE CASH FLOW
Cash From Operating Activities	-$1.560M	-$1.420M	-$560.0K
Capital Expenditures	-$160.0K	-$110.0K	-$100.0K
Free Cash Flow	-$1.400M	-$1.310M	-$460.0K
YoY Change	-13.58%	184.78%	-58.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	78189173	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	7610360	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3281613	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7097737	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3512	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	3786067	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1602294	USD
CY2013Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1919220	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3211942	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1488465	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	3521514	USD
CY2013Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4003494	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3446211	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	253232	USD
CY2013Q4	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	110289	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6121895	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	152180	USD
CY2013Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	77910	USD
CY2012Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	66203	USD
CY2013Q4	snti	Common Stock To Be Issued Upon Conversion Of Convertible Preferred Stock CommonStockToBeIssuedUponConversionOfConvertiblePreferredStock	232000	shares
CY2013Q4	snti	Number Of Diluted Options Outstanding NumberOfDilutedOptionsOutstanding	275319	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2012Q4	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	106516	USD
CY2013Q4	snti	Number Of Diluted Warrants Outstanding NumberOfDilutedWarrantsOutstanding	5682661	shares
CY2013Q4	snti	Potential Dilutive Shares Of Common Stock PotentialDilutiveSharesOfCommonStock	6189980	shares
CY2012Q4	us-gaap	Share Based Compensation ShareBasedCompensation	196567	USD
CY2013Q4	us-gaap	Share Based Compensation ShareBasedCompensation	342791	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0175	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0266	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.99	pure
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4555	USD
CY2013Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3566497	USD
CY2013Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2187082	USD
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	99728	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	99728	USD
CY2013Q2	us-gaap	Liabilities Liabilities	3311670	USD
CY2013Q4	us-gaap	Liabilities Liabilities	3381341	USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	637320	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	477628	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	387540	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	616903	USD
CY2013Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2187082	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3482388	USD
CY2013Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	5171	USD
CY2013Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	5171	USD
CY2013Q2	us-gaap	Assets Assets	7097737	USD
CY2013Q4	us-gaap	Assets Assets	11101431	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	22721	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	49573	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	85542557	USD
CY2013Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	74425835	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	77872046	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	7720090	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11101431	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	252233	USD
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P17Y
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	129128	USD
CY2012Q4	snti	Common Stock To Be Issued Upon Conversion Of Convertible Preferred Stock CommonStockToBeIssuedUponConversionOfConvertiblePreferredStock	38269	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	275319	shares
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35996534	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1441688	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1882233	USD
CY2012Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	708968	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24696513	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1104512	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1374242	USD
CY2012Q4	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2013Q4	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Costs And Expenses CostsAndExpenses	3441636	USD
CY2012Q4	us-gaap	Costs And Expenses CostsAndExpenses	1300047	USD
CY2013Q4	us-gaap	Costs And Expenses CostsAndExpenses	1588907	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2546200	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3341636	USD
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1300047	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1588907	USD
CY2012Q4	snti	Number Of Diluted Warrants Outstanding NumberOfDilutedWarrantsOutstanding	318973	shares
	snti	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod	27788	shares
CY2012Q4	snti	Number Of Diluted Options Outstanding NumberOfDilutedOptionsOutstanding	211740	shares
CY2012Q4	snti	Potential Dilutive Shares Of Common Stock PotentialDilutiveSharesOfCommonStock	568982	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	73848	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	35957	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y1M6D
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	657	shares
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P45M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	46780	shares
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	201154	USD
	snti	Probability To Achieve Employee Target Goals ProbabilityToAchieveEmployeeTargetGoals	0.62	pure
	us-gaap	Share Based Compensation ShareBasedCompensation	350129	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	467257	USD
	snti	Unrecognized Share Based Compensation Expense UnrecognizedShareBasedCompensationExpense	691000	USD
CY2013Q4	snti	Issuance Of Additional Options IssuanceOfAdditionalOptions	27300	shares
	snti	Options Aggregated During Period OptionsAggregatedDuringPeriod	111210	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0165	pure
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0266	pure
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.99	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	231748	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	74080	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2721	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	196822	shares
CY2013Q4	snti	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable And Expected To Be Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndExpectedToBeExercisableNumber	262795	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.22
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.39
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2010Q1	us-gaap	Line Of Credit Facility Interest Rate Description LineOfCreditFacilityInterestRateDescription	Line of Credit accrue at an annual interest rate of (i) the broker rate in effect at the interest date (which was 3.75% at December 31, 2013), plus (ii) 2.0% and are due on demand. There are no other conditions or fees associated with the Line of Credit.
CY2013Q2	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	2187082	USD
CY2013Q4	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	2187082	USD
	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	69776	USD
	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	64350	USD
CY2012Q4	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	34786	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.50
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	255.88
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.98
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	33.97
CY2013Q2	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit	4.30
	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercised In Period Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisedInPeriodExercisePrice	0
	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Cancelled In Period Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansCancelledInPeriodExercisePrice	16.50
CY2013Q4	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit	4.30
CY2013Q2	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit	345
CY2013Q4	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit	345
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2272062	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4957275	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2272062	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4957275	shares
CY2010Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	3000000	USD
CY2010Q1	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.0375	pure
CY2010Q1	snti	Line Of Credit Spread Over Base Rate LineOfCreditSpreadOverBaseRate	0.020	pure
CY2013Q4	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	32153	USD
CY2013Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1602294	USD
CY2013Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6121895	USD
	us-gaap	Licenses Revenue LicensesRevenue	1890000	USD
	us-gaap	Licenses Revenue LicensesRevenue	0	USD
	us-gaap	Licenses Revenue LicensesRevenue	100000	USD
CY2012Q4	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2013Q4	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2013Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	941784	USD
CY2012Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	591079	USD
CY2013Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	647123	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2158595	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Costs And Expenses CostsAndExpenses	62851642	USD
	us-gaap	Costs And Expenses CostsAndExpenses	2546200	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-60961642	USD
	us-gaap	Revenue From Grants RevenueFromGrants	244479	USD
	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2012Q4	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2013Q4	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	8701721	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	44292	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	0	USD
CY2012Q4	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	64440	USD
CY2013Q4	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	0	USD
	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	586442	USD
	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0	USD
	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0	USD
CY2012Q4	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0	USD
CY2013Q4	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	205390	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2012Q4	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2013Q4	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1724546	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-785171	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2012Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2013Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-361877	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11227870	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2012Q4	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2013Q4	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	2027930	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2012Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2013Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	102566	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-68260	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-62335	USD
CY2012Q4	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-34278	USD
CY2013Q4	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-30731	USD
	us-gaap	Net Income Loss NetIncomeLoss	-66463267	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3355339	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3403971	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-1269885	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-1619638	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	11408779	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	648155	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	42240	USD
CY2012Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	23986	USD
CY2013Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	20617	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-77872046	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4003494	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3446211	USD
CY2012Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1293871	USD
CY2013Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1640255	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2012Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-77872046	USD
CY2012Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1293871	USD
CY2013Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1640255	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.57
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.20
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	153223	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1547157	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	130420	USD
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.48
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1122123	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2875517	shares
CY2012Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1169753	shares
CY2013Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3443109	shares
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	101769	USD
	snti	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	290	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
	us-gaap	Dividends Dividends	14500	USD
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	85179	USD
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	0	USD
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	0	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	131250	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	9022980	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	44292	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	115869	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	0	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	2003386	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	53800	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	13297903	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	10000000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1227869	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	snti	Gain Loss On Settlement Of Warrant Liabilities GainLossOnSettlementOfWarrantLiabilities	-1724546	USD
	snti	Gain Loss On Settlement Of Warrant Liabilities GainLossOnSettlementOfWarrantLiabilities	-785171	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1488465	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-252976	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-430755	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	5171	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	0	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	477628	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	491115	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-159692	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	777404	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	187951	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	234863	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43017420	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1201869	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2092404	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7005705	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	185947	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1281	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Interest Paid InterestPaid	64351	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7191652	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-253514	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-253232	USD
	snti	Proceeds From Government Grant ProceedsFromGovernmentGrant	99728	USD
	snti	Proceeds From Government Grant ProceedsFromGovernmentGrant	0	USD
	snti	Proceeds From Government Grant ProceedsFromGovernmentGrant	0	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	2187082	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
	snti	Proceeds From Issuance Of Preferred Stock And Warrants Net ProceedsFromIssuanceOfPreferredStockAndWarrantsNet	10754841	USD
	snti	Proceeds From Issuance Of Preferred Stock And Warrants Net ProceedsFromIssuanceOfPreferredStockAndWarrantsNet	0	USD
	snti	Proceeds From Issuance Of Preferred Stock And Warrants Net ProceedsFromIssuanceOfPreferredStockAndWarrantsNet	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	2160986	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	651781	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	36237083	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	94183	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	6865237	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	56330967	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	94183	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6865237	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6121895	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1361200	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4519601	USD
CY1998Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2001325	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	640125	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	4953	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1378	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	731	USD
	snti	Warrants Issued For Financing Costs WarrantsIssuedForFinancingCosts	690984	USD
	snti	Warrants Issued For Financing Costs WarrantsIssuedForFinancingCosts	0	USD
	snti	Warrants Issued For Financing Costs WarrantsIssuedForFinancingCosts	0	USD
	snti	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	-14500	USD
	snti	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	-89598	USD
	snti	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	-14500	USD
	us-gaap	Interest Paid InterestPaid	558488	USD
	us-gaap	Interest Paid InterestPaid	69776	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Note 1 - Basis of Presentation:</font></font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The financial statements included herein have been prepared by Senesco Technologies, Inc. (the “Company”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Certain information and footnote disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2013, as amended.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">The Company’s board of directors authorized a 1:100 reverse stock split on September 30, 2013, to take effect on October 21, 2013.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> All share and related option and warrant information presented in these financial statements and accompanying footnotes have been retroactively adjusted to reflect the reduced number of shares resulting from this action.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting solely of those which are of a normal recurring nature, necessary to present fairly its financial position as of December 31, 2013 and the results of its operations for the three months and six months ended December 31, 2013 and cash flows for the six months ended December 31, 2013.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black"><font style="FONT-SIZE: 10pt">Interim results are not necessarily indicative of results for the full fiscal year.</font></font></div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	365488	USD
	snti	Cash Paid For Fractional Shares Due To Reverse Split CashPaidForFractionalSharesDueToReverseSplit	303	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Trading Symbol TradingSymbol	SNTI
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5042275	shares
	dei	Entity Registrant Name EntityRegistrantName	SENESCO TECHNOLOGIES INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001035354
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company

Files In Submission

Name	View Source	Status
0001144204-14-009665-index-headers.html	Edgar Link	pending
0001144204-14-009665-index.html	Edgar Link	pending
0001144204-14-009665.txt	Edgar Link	pending
0001144204-14-009665-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snti-20131231.xml	Edgar Link	completed
snti-20131231.xsd	Edgar Link	pending
snti-20131231_cal.xml	Edgar Link	unprocessable
snti-20131231_def.xml	Edgar Link	unprocessable
snti-20131231_lab.xml	Edgar Link	unprocessable
snti-20131231_pre.xml	Edgar Link	unprocessable
v366663_10q.htm	Edgar Link	pending
v366663_ex31-1.htm	Edgar Link	pending
v366663_ex31-2.htm	Edgar Link	pending
v366663_ex32-1.htm	Edgar Link	pending
v366663_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox

2014 Q1 Form 10-Q Financial Statement

#000114420414009665 Filed on February 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELOX Eloxx Pharmaceuticals, Inc. Stock $elox

2014 Q1 Form 10-Q Financial Statement

#000114420414009665 Filed on February 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox